Breaking News

Oxford Biomedica Expands Global Reach with ABL Europe Acquisition

Strengthens its position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UK.

Author Image

By: Charlie Sternberg

Associate Editor

Oxford Biomedica plc, a quality and innovation-led cell and gene therapy CDMO, has completed its previously announced acquisition of ABL Europe SAS from Institut Mérieux SA.   According to the company, the acquisition of ABL Europe, a pure-play European CDMO, strengthens Oxford Biomedica’s position as a leading cell and gene therapy CDMO. Benefits of the Acquisition This strategic move broadens the Company’s international development, manufacturing and testing presence, servic...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters